Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
LIGAND PHARMACEUTICALS INC | Director | Common Stock | 5.4K | $468K | $86.65 | Jun 14, 2024 | Direct |
Syros Pharmaceuticals, Inc. | Chief Financial Officer | Restricted Stock Units | 26.7K | $137K | $5.12 | Mar 31, 2024 | Direct |
Syros Pharmaceuticals, Inc. | Chief Financial Officer | Common Stock | 24.6K | $126K | $5.12 | Apr 1, 2024 | Direct |
LIGAND PHARMACEUTICALS INC | Director | Non-Qualified Stock Option (right to buy) | 5.44K | Jun 14, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
LGND | LIGAND PHARMACEUTICALS INC | Jun 14, 2024 | 2 | $0 | 4 | Jun 18, 2024 | Director |
SYRS | Syros Pharmaceuticals, Inc. | Mar 31, 2024 | 5 | -$24.2K | 4 | Apr 2, 2024 | Chief Financial Officer |
SYRS | Syros Pharmaceuticals, Inc. | Oct 31, 2023 | 3 | -$14K | 4 | Nov 2, 2023 | Chief Financial Officer |
LGND | LIGAND PHARMACEUTICALS INC | Jun 9, 2023 | 2 | $0 | 4 | Jun 13, 2023 | Director |
SYRS | Syros Pharmaceuticals, Inc. | Mar 31, 2023 | 3 | -$1.61K | 4 | Apr 4, 2023 | Chief Financial Officer |
SYRS | Syros Pharmaceuticals, Inc. | Feb 16, 2023 | 1 | $0 | 4 | Feb 21, 2023 | Chief Financial Officer |
SYRS | Syros Pharmaceuticals, Inc. | Oct 6, 2022 | 2 | $0 | 4 | Oct 11, 2022 | Chief Financial Officer |
LGND | LIGAND PHARMACEUTICALS INC | Jun 29, 2022 | 2 | $0 | 4 | Jun 30, 2022 | Director |
LGND | LIGAND PHARMACEUTICALS INC | Jun 29, 2022 | 0 | $0 | 3 | Jun 29, 2022 | Director |
SYRS | Syros Pharmaceuticals, Inc. | Feb 15, 2022 | 2 | $0 | 4 | Feb 17, 2022 | Chief Financial Officer |
SYRS | Syros Pharmaceuticals, Inc. | Oct 12, 2021 | 1 | $0 | 4 | Oct 13, 2021 | Chief Financial Officer |
SYRS | Syros Pharmaceuticals, Inc. | Oct 12, 2021 | 0 | $0 | 3 | Oct 13, 2021 | Chief Financial Officer |